title: Markers of resistance to anti-EGFR therapy in colorectal cancer.
abstract: Epidermal growth factor receptor (EGFR) is a therapeutic target in colorectal cancer (CRC). The benefit from EGFR inhibitors appears to be limited to a subset of patients with CRC. Mechanisms of resistance to EGFR inhibitors are being identified. KRAS codon 12 activating mutation is a predominate mechanism of resistance to EGFR inhibitors in around 40% of patients with advanced CRC. Other potential mechanisms of resistance include ligand expression, increased EGFR number, mutations of BRAF and activation of alternate signaling pathways.
authors.affiliation: Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
authors.forename: Walid
authors.initials: W
authors.lastname: Shaib
authors.forename: Reena
authors.initials: R
authors.lastname: Mahajan
authors.forename: Bassel
authors.initials: B
authors.lastname: El-Rayes
keywords: Resistance; anti-epidermal growth factor receptor (anti-EGFR); colorectal cancer